Novo Nordisk is doubling down on its collaboration with Valo Health, committing up to $190 million in near-term payments—and ...

The deal extends an agreement to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease ...

Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of drugs that are allowed to be compounded. In a Citizen Petition posted on ...

While Novo Nordisk has established a strong position in metabolic disease with the GLP-1 agonist semaglutide, marketed as Ozempic for type 2 diabetes and Wegovy for obesity, the pharmaceutical ...

rendering these products less effective or ineffective for conditions such as type 2 diabetes, cardiovascular disease, and chronic weight management. Novo Nordisk also noted 44 documented adverse ...